Table 1.
Prediction of 3-Month ADM treatment response in the test sample in three group defined by predicted probabilities in the training sample (n=198)
| Distribution | PPV | Cumulative PPV | Sensitivity | Cumulative Sensitivity | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| % | (SE) | % | (SE) | % | (SE) | % | (SE) | % | (SE) | |
|
|
|
|
|
|
||||||
| High | 50.4a | (4.1) | 45.7b | (5.5) | 45.7 | (5.5) | 64.7 | (6.7) | 64.7 | (6.7) |
| Intermediate | 30.1c | (3.9) | 34.5d | (7.6) | 41.5 | (4.5) | 29.2 | (6.6) | 93.9 | (2.7) |
| Low | 19.4 | (3.3) | 11.1 | (4.9) | 35.6 | (3.9) | 6.0 | (2.7) | 100.0 | -- |
Abbreviations: ADM, antidepressant medication; PPV, positive predictive value (i.e., predicted proportion with treatment response); SE, standard error; SN, sensitivity (i.e., proportion of all treatment responders).
a
80.9% among patients with mild baseline symptom severity versus 35.3% among other patients.
b
47.5% among patients with mild baseline symptom severity versus 45.7% among other patients.
c
13.7% in the subsample of patients with mild baseline symptom severity versus 38.3% among other patients.
d
30.3% among patients with mild baseline symptom severity versus 38.4% among other patients.